^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    GSPT1 deletion

    i
    Other names: GSPT1, G1 To S Phase Transition 1, Eukaryotic Peptide Chain Release Factor GTP-Binding Subunit ERF3A, Eukaryotic Peptide Chain Release Factor Subunit 3a, G1 To S Phase Transition Protein 1 Homolog, Eukaryotic Release Factor 3a, ERF3a, 551G9.2, ETF3A, ERF3A, GST1
    Entrez ID:
    2935
    29d
    Construction of ceRNA Network and Disease Diagnosis Model for Keloid Based on Tumor Suppressor ERRFI1. (PubMed, Exp Dermatol)
    The ceRNA network may provide new clues to the potential pathogenesis of KD. Finally, the new KD diagnostic model could be an effective tool for assessing the risk of KD development.
    Journal
    |
    ERRFI1 (ERBB Receptor Feedback Inhibitor 1) • MIR148A (MicroRNA 148a)
    |
    GSPT1 deletion • ERRFI1 deletion
    1year
    MIG6 mediates adaptive and acquired resistance to ALK/ROS1 fusion kinase inhibition through EGFR bypass signaling. (PubMed, Mol Cancer Ther)
    A MIG6 deletion was also found in a patient after progressing to ROS1 inhibition. Collectively, this study identifies MIG6 as a novel regulator for EGFR-mediated adaptive and acquired resistance to ALK/ROS1 inhibitors and suggests EGFR to MIG6 ratios and MIG6 damaging alterations as biomarkers to predict responsiveness to ALK/ROS1 and EGFR inhibitors.
    Preclinical • Journal
    |
    ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • ERRFI1 (ERBB Receptor Feedback Inhibitor 1)
    |
    EGFR mutation • ALK mutation • ROS1 fusion • GSPT1 deletion • ALK-ROS1 fusion • ERRFI1 deletion